Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Find out which cash back credit cards have no annual fee to suit your spending habits. Discover the perfect card for you today!
27,937 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
SpaceX used its soaring stock to fund a $60 billion Cursor acquisition in stock, turning a fresh IPO into a powerful ...
Barclays has boosted its Ionis target to $106, signaling a roughly 46% upside from recent levels as olezarsen eyes pe...
When a company's CFO sells a chunk of shares, investors want to know what it means. This guide explains the implicati...
Unity Software’s latest guidance sparked a sharp rally, underscoring how Vector AI could redefine monetization in int...
Tesla sits at a fair-value crossroads in 2026, with capex and AI initiatives guiding a modest upside. Here’s how inve...
The headline question is tempting: is the u.s. market broken? The reality is more nuanced. This guide breaks down wha...
When markets swing, fear can push you to sell at the worst moment. This guide shows practical, actionable steps to tu...
A senior Rogers Corp. executive sold 830 shares for about $113,000, sparking questions about what it means for the st...
A sudden stock pullback creates a rare entry point for patient investors. The company combines non-discretionary serv...
Hut 8 is pivoting to AI data center infrastructure, prompting a Canaccord upgrade that nearly doubles the firm’s pric...
Prices move where buyers meet sellers. This article digs into whether supply and demand can truly forecast stock move...